- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00013286
A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk
This project will identify risk factors for diabetic foot ulcer by studying the relationship between endothelial dysfunction and foot ulcer risk. A fundamental defect in type 1 and 2 diabetic subjects is impaired vasodilatory reserve which is reflected in the dysfunction of endothelium-dependent vasodilation. Findings thus far point to an important role of the microvasculature in the development of diabetic foot ulcer and amputation.
In this study a a well-characterized cohort of 750 diabetic veterans without foot ulcer will be followed over 3-years.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prevention of foot ulcer should result in a reduction in the risk of lower limb amputation. We propose to identify risk factors for diabetic foot ulcer by studying the relationship between endothelial dysfunction and foot ulcer risk. It has been proposed that impaired vasoregulation in diabetic patients leads to the development and perpetuation of chronic foot ulceration via failure of the normal hyperemic response to injury. A fundamental defect that has been demonstrated in type 1 and 2 diabetic subjects is impaired vasodilatory reserve, which reflects dysfunction of endothelium-dependent vasodilation. Our findings thus far point to an important role of the microvasculature in the development of diabetic foot ulcer and amputation, with our demonstration of higher foot ulcer and lower-limb amputation risk in relation to lower dorsal foot transcutaneous oxygen level. The role of endothelial dysfunction in relation to diabetic foot ulcer risk has not previously been studied.
We will follow a well-characterized cohort of 750 diabetic veterans without foot ulcer over 3-year after obtaining baseline measures of endothelial function using iontophoretic application of acetylcholine to induce cutaneous endothelium-dependent vasodilation on the dorsal foot. Iontophoresis permits noninvasive delivery of ionic drugs cutaneously without damage to the skin or systemic effects. Change in microvascular flow will be measured using a laser Doppler imager (Moor LDI) over a 4x4 cm area divided into 18496 measurement sites. Endothelial function will be defined as the difference between readings before and after the iontophoretic application of a 1% acetylcholine solution at a current of 0.2 mA for 1 minute, with higher readings reflecting better endothelial function. These techniques are the accepted standard method for assessment of endothelium-dependent vasodilation in the cutaneous microvasculature. Additional measurements will be obtained on other ulcer risk factors to assess whether endothelial dysfunction independently influences foot ulcer risk, or whether it is merely a marker for different pathophysiologic conditions responsible for higher risk (eg., sensory neuropathy). Possible confounding factors considered will include sensory and autonomic neuropathy; dorsal foot transcutaneous oximetry; macrovascular function assessed with Doppler blood pressures; diabetes characteristics; in-shoe plantar pressure (F-scan), medication use, and foot deformity.
Study Type
Enrollment
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States
- VAMC, Seattle, WA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Investigators
- John Fryer, Ph.D. Asst. Director, Program Analysis and Review Section (PARS), Rehabilitation Research & Development Service
- Wijegupta Ellepola, Program Analyst, Program Analysis & Review Section (PARS), Rehabilitation Research & Development Service
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A2016R
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcers
-
CytomedixCTI Clinical Trial and Consulting ServicesTerminatedDiabetic Foot Ulcers | Wounds | Pressure Ulcers | Leg UlcersUnited States
-
HealthpointCompletedDiabetic Foot Ulcers (DFU) | Venous Stasis Ulcers (VSU)United States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Arteriocyte, Inc.TerminatedDiabetic Foot Ulcers | Pressure Ulcers | Venous UlcersUnited States
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Pressure UlcersUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States, Canada
-
HealthpointCompleted
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States
-
Oneness Biotech Co., Ltd.Completed
Clinical Trials on Prevention Diabetic Foot Ulcer
-
Bolan Medical Complex Hospital Quetta PakistanCompletedDiabetic Foot | Amputation | Diabetic Foot Ulcer | Antibiotic Resistant StrainPakistan
-
Istanbul Medeniyet UniversityCompletedDiabetic Foot, Mobile Application, Patient Education
-
Helen ObilorWounds CanadaCompleted
-
Winthrop University HospitalWithdrawnType 2 Diabetes | Diabetic Foot Ulcer | Diabetic NeuropathyUnited States
-
Tenex Health Inc.Trice MedicalNot yet recruiting
-
Okayama UniversityCompletedDiabetic Peripheral NeuropathyJapan
-
Medical University of WarsawPolish Stem Cells Bank S.A.Completed
-
Integra LifeSciences CorporationCompletedDiabetic Foot UlcersUnited States
-
US Department of Veterans AffairsCompletedDiabetic Foot UlcersUnited States
-
European Egyptian Pharmaceutical IndustriesTerminatedDiabetic Foot UlcerEgypt